• About
  • Overview
  • Management
    • Dr. Joe Lewis
    • Dr. Bernd Janssen
    • Sally-Anne Watson
  • Supervisory Board
  • Scientific Advisory Board
  • Prof. Frank Giles
  • Investors
• Programs
  • Mechanism of Action
  • Technology
  • Products
  • Technology Fact Sheet
• News
  • Latest News
  • Upcoming Events
  • Download Area
• Careers
  • Vacancies
• Contact
  • Contact
• Home
  • Home

Welcome to Elara Pharmaceuticals

ELARA Pharmaceuticals GmbH is a pre-clinical stage biopharmaceutical company founded in 2006 as a spin-out of the European Molecular Biology Laboratory (EMBL) in Heidelberg.

The company focuses on the development of novel treatments for malignant diseases through inhibition of the hypoxia signaling pathway (HIF), which is crucial for tumor survival and growth, and through induction of apoptosis. Since HIF is upstream of validated oncology targets, this approach is expected to yield drugs of superior efficacy to current standards of care.